# Janssen, LP clinical trials: 20 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Janssen, LP as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Janssen, LP: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/janssen-lp

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 14, 2007 | NCT00558298 | A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder. | Janssen, LP | Phase 3 | Completed | Schizophrenia, Schizoaffective Disorder | 811 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00558298) |
| July 2, 2007 | NCT00495118 | A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients. | Janssen, LP | Phase 3 | Completed | Schizophrenia, Schizoaffective Disorder | 314 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00495118) |
| September 19, 2006 | NCT00378183 | A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful... | Janssen, LP | Phase 4 | Completed | Schizoaffective Disorder, Schizophrenia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00378183) |
| December 5, 2005 | NCT00261430 | A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone. | Janssen, LP | Phase 4 | Completed | Schizophrenia | 650 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00261430) |
| November 15, 2005 | NCT00253136 | A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia | Janssen, LP | Phase 3 | Completed | Schizophrenia, Psychotic Disorders | 458 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00253136) |
| November 15, 2005 | NCT00253123 | A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia | Janssen, LP | Phase 3 | Completed | Dementia, Alzheimer Disease, Dementia, Vascular | 626 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00253123) |
| November 15, 2005 | NCT00253110 | A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder | Janssen, LP | Phase 4 | Completed | Schizophrenia, Schizoaffective Disorder | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00253110) |
| November 7, 2005 | NCT00249132 | A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia | Janssen, LP | Phase 3 | Completed | Schizophrenia, Psychotic Disorders | 523 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00249132) |
| November 7, 2005 | NCT00249119 | A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia | Janssen, LP | Phase 3 | Completed | Schizophrenia, Psychotic Disorder | 1,579 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00249119) |
| October 31, 2005 | NCT00246194 | Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA) | Janssen, LP | Observational | Completed | Schizophrenia | 532 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00246194) |
| October 12, 2005 | NCT00236379 | A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder | Janssen, LP | Phase 4 | Completed | Schizophrenia, Diabetes Mellitus | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00236379) |
| October 12, 2005 | NCT00236353 | Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder | Janssen, LP | Phase 3 | Completed | Schizophrenia, Psychotic Disorders | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00236353) |
| August 31, 2001 | NCT00002438 | A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients | Janssen, LP | Not applicable | Completed | HIV Infections, Histoplasmosis | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002438) |
| August 31, 2001 | NCT00002370 | Study of Itraconazole in Patients With Advanced HIV Infection | Janssen, LP | Not applicable | Completed | HIV Infections | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002370) |
| August 31, 2001 | NCT00002341 | A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not... | Janssen, LP | Not applicable | Completed | Candidiasis, Oral, HIV Infections | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002341) |
| August 31, 2001 | NCT00002278 | A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS | Janssen, LP | Not applicable | Completed | Cryptosporidiosis, HIV Infections | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002278) |
| August 31, 2001 | NCT00002159 | A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by... | Janssen, LP | Phase 3 | Completed | HIV Infections, Histoplasmosis, Blastomycosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002159) |
| August 31, 2001 | NCT00002133 | An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in... | Janssen, LP | Not applicable | Completed | Candidiasis, Oral, HIV Infections | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002133) |
| August 31, 2001 | NCT00002027 | Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433) | Janssen, LP | Not applicable | Completed | Cryptosporidiosis, HIV Infections | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002027) |
| November 1, 1999 | NCT00000172 | Evaluation of Galantamine in the Treatment of Alzheimer's Disease | Janssen, LP | Phase 3 | Completed | Alzheimer Disease | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00000172) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 3 | 9 |
| Phase 4 | 4 |
| Not applicable | 6 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 11 |
| Psychotic Disorders | 8 |
| HIV Infections | 7 |
| Acquired Immunodeficiency Syndrome | 7 |
| AIDS-Related Complex | 3 |
| Histoplasmosis | 2 |
| Cryptosporidiosis | 2 |
| AIDS-Related Opportunistic Infections | 2 |
| Diarrhea | 2 |
| Candidiasis, Oral | 2 |
| Alzheimer Disease | 2 |
| Diabetes Mellitus | 1 |
| Blastomycosis | 1 |
| Mental Disorders | 1 |
| Catatonia | 1 |
| Dementia | 1 |
| Dementia, Vascular | 1 |
| Mixed Dementias | 1 |
| Weight Loss | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Forestry services in the United States](https://specstream.ai/data/businesses/forestry-services/united-states)
- [Pan Asian restaurants in the United States](https://specstream.ai/data/businesses/pan-asian-restaurants/united-states)
- [Venezuelan restaurants in the United States](https://specstream.ai/data/businesses/venezuelan-restaurants/united-states)
- [Commercial refrigeration companies in the United States](https://specstream.ai/data/businesses/commercial-refrigeration-companies/united-states)
- [Insurance agencies in the United States](https://specstream.ai/data/businesses/insurance-agencies/united-states)
- [Rehabilitation centers in the United States](https://specstream.ai/data/businesses/rehabilitation-centers/united-states)
